dual-acting oral drug
Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial
Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist
Actionable Insights Powered by AI
Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist